A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial. (October 2016)

• Record Type: Journal Article
• Authors: Roviello, Giandomenico; Milani, Manuela; Gobbi, Angela; Dester, Martina; Cappelletti, Maria Rosa; Allevi, Giovanni; Aguggini, Sergio; Ravelli, Andrea; Gussago, Francesca; Cocconi, Alessandra; Zanotti, Laura; Senti, Chiara; Strina, Carla; Bottini, Alberto; Generali, Daniele
• Is Part Of: Future oncology. Volume 12:Number 19(2016)
• Page Start: 2189
• Page End: 2193
• Publication Date: 2016-10
• Subjects: BRCA -- olaparib -- triple-negative breast cancer; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0116
• Languages: English
• ISSNs: 1479-6694

Abstract

The OLTRE trial (ClinicalTrials.gov number: NCT02681562) is an open-label, 'window of opportunity' Phase II controlled trial to evaluate the biological activity of olaparib in locally advanced triple-negative breast cancer compared with other subtypes of locally advanced breast cancer patients carrying germinal BRCA mutation receiving olaparib with the same treatment approach. The primary end point is to investigate the correlation between baseline gene and protein expression profile in order to identify possible predictive markers of response to olaparib. The OLTRE trial is expected to identify the surrogate markers of the biological activity of olaparib in the treatment of patients with triple-negative breast cancer.